Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

HealthLynked (HLYK) Cash & Equivalents (2016 - 2025)

HealthLynked (HLYK) has disclosed Cash & Equivalents for 10 consecutive years, with $10911.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 27.06% to $10911.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $10911.0, a 27.06% decrease, with the full-year FY2024 number at $76241.0, down 69.16% from a year prior.
  • Cash & Equivalents was $10911.0 for Q3 2025 at HealthLynked, down from $20201.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $5.4 million in Q3 2021 to a low of $10911.0 in Q3 2025.
  • A 5-year average of $1.2 million and a median of $172700.0 in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 1929.58% in 2021, then plummeted 99.42% in 2024.
  • HealthLynked's Cash & Equivalents stood at $3.3 million in 2021, then crashed by 98.12% to $61891.0 in 2022, then surged by 299.45% to $247222.0 in 2023, then tumbled by 69.16% to $76241.0 in 2024, then plummeted by 85.69% to $10911.0 in 2025.
  • Per Business Quant, the three most recent readings for HLYK's Cash & Equivalents are $10911.0 (Q3 2025), $20201.0 (Q2 2025), and $22270.0 (Q1 2025).